Special Issue

Advances in Chronic Lymphocytic Leukemia Microenvironment: The Disruption of the Supportive Leukemic/Accessory Cells Interactions to Improve Therapy Response

Message from the Guest Editors

Chronic Lymphocytic leukemia (CLL) is a lymphoproliferative disorder characterized by the relentless accumulation of leukemic B cells in the blood, secondary lymphoid tissue and bone marrow. It has become increasingly clear that the stimuli derived by the cross-talk between the neoplastic cells and the microenvironment have a critical role in CLL-pathogenesis: this finding suggests the importance of disrupting survival advantages conferred by growth-favorable niches to improve the response to therapy. Indeed, several cytokines released within the microenvironment and specific cell–cell contacts favor clonal B cells expansion and resistance to drug treatments. It is further worth noting that leukemic B cells shape their microenvironment and polarize *M1* vs. *M2* or *Th1* vs. *Th2* cells, causing, therefore, suppression of the immune response. This Special Issue encompasses new research articles and reviews to advance our knowledge in CLL–TME cross-talk and to highlight novel treatments optimized to reshape the protumor microenvironment and to potentiate current therapies.

Guest Editors

Dr. Daniela De Totero

Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Dr. Paolo Giannoni

Department of Experimental Medicine, University of Genoa, Genoa, Italy

Deadline for manuscript submissions

closed (15 September 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/138124

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)